Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.17 $780 - $1,521
1,300 New
1,300 $0
Q1 2023

May 15, 2023

BUY
$1.03 - $1.8 $721 - $1,260
700 Added 140.0%
1,200 $1,000
Q4 2022

Feb 14, 2023

SELL
$1.7 - $30.2 $234,600 - $4.17 Million
-138,000 Reduced 99.64%
500 $0
Q3 2022

Nov 14, 2022

BUY
$1.9 - $27.7 $192,280 - $2.8 Million
101,200 Added 271.31%
138,500 $364,000

Others Institutions Holding EVAX

# of Institutions
1
Shares Held
37.5K
Call Options Held
0
Put Options Held
0

About Evaxion Biotech A/S


  • Ticker EVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,977,900
  • Market Cap $35.7M
  • Description
  • Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...
More about EVAX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.